| Literature DB >> 33859367 |
Regine Söntgerath1, Julia Däggelmann2, Sabine V Kesting3,4, Corina S Rueegg5, Torge-Christian Wittke6, Simon Reich7, Katharina G Eckert8, Sandra Stoessel9, Carolina Chamorro-Viña10, Joachim Wiskemann7, Peter Wright11, Anna Senn-Malashonak12, Vanessa Oschwald2, Anne-Marie Till13, Miriam Götte14.
Abstract
BACKGROUND: Research indicates reduced physical performance from diagnosis into survivorship of pediatric cancer patients. However, there is no systematic information or guideline available on the methods to assess physical performance and function in this population. The purpose was to systematically compile and describe assessments of physical performance and function in patients and survivors of pediatric cancer, including cardiorespiratory fitness, muscle strength, speed, balance, flexibility, functional mobility, gait and motor performance test batteries.Entities:
Mesh:
Year: 2021 PMID: 33859367 PMCID: PMC9064803 DOI: 10.1038/s41390-021-01523-5
Source DB: PubMed Journal: Pediatr Res ISSN: 0031-3998 Impact factor: 3.953
Fig. 1PRISMA flow diagram showing the reference selection process.
*Reasons for exclusion: less than 75% of the population were diagnosed with cancer measure of either physical or functional performance (n = 55), any non-original articles (e.g. reviews, congress abstracts, commentaries or letters without data) (n = 31), duplicates that were not identified as such before (n = 10), (v) studies without description of assessment used (n =9), (vi) studies/assessment with less than five participants (n = 11), or (vii) full-texts that were not available in English or German (n = 13).
Fig. 2Number of studies for each outcome measure, indicating the phase of therapy in which the studies were conducted.
Please note: The sum of assessments in Fig. 2 (n = 282) is greater than the number of all included studies (n = 149), because in many studies assessments from several categories were included.
Fig. 3Distribution of the types of cancer (%) that were included in the assessments of the eight categories of physical performance and function.
The bar on the far right shows the incidence of childhood cancer as a reference. Note: Number of persons tested specified here (e.g. n = 8136 for cardiorespiratory fitness) differs from number of study participants (n = 7936, see section on cardiorespiratory fitness above), because some study participants were tested using several test methods.
Summary of study methods assessing cardiorespiratory fitness in pediatric oncology.
| Assessment | No. of studies | Total sample sizea | Type of cancer | Age in years (range) | Phases of treatment | Validityc | Reliabilityc | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leukemia/lymphoma | Bone tumor | CNS tumor | Otherb | During | Maint. | Off | ||||||
| Maximal CPET | 33 | 1170 | ✓ | ✓ | ✓ | ✓ | 3.5–41 | ✓ | ✓ | ✓ | – | – |
| 6MWT | 26 | 6180 | ✓ | ✓ | ✓ | ✓ | 3.5–63.8 | ✓ | ✓ | ✓ | – | – |
| Submaximal CPET | 5 | 457 | ✓ | – | ✓ | ✓ | 7–44.6 | – | – | ✓ | – | – |
| 9MWT | 4 | 154 | ✓ | ✓ | – | ✓ | 4–27 | – | ✓ | ✓ | ✓ | ✓ |
| Wingate anaerobic test | 3 | 58 | ✓ | – | – | ✓ | 7.7–23.8 | – | – | ✓ | – | – |
| 2MWT | 2 | 91 | ✓ | – | ✓ | ✓ | 6–45 | – | ✓ | ✓ | – | – |
| PACER | 2 | 25 | ✓ | – | ✓ | – | 4–18 | – | ✓ | ✓ | – | – |
2MWT 2-minute walk test, 6MWT 6-minute walk test, 9MWT 9-minute walk test, CPET cardiopulmonary exercise test, maint. maintenance treatment, No. number, PACER progressive aerobic cardiovascular endurance run.
aOnly study participants who performed the assessments were counted.
bIncluding other cancer diagnoses and diagnoses that were not clearly specified.
cIf evaluated in a childhood cancer population.
Summary of study methods assessing motor performance in test batteries in pediatric oncology.
| Assessment | No. of studies | Total sample sizea | Type of cancer | Age in years (range) | Phases of treatment | Validityc | Reliabilityc | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leukemia/lymphoma | Bone tumors | CNS tumors | Otherb | active | Maint. | Off | ||||||
| BOT-2 | 10 | 327 | ✓ | ✓ | ✓ | ✓ | 4–22 | ✓ | – | ✓ | – | – |
| BOT-2 SF | 6 | 384 | ✓ | – | – | – | 4–18 | ✓ | ✓ | ✓ | – | – |
| m-ABC | 5 | 283 | ✓ | – | – | ✓ | 4.0–19.3 | ✓ | – | ✓ | – | – |
| BOTMP | 5 | 164 | ✓ | – | – | ✓ | 1.75–25.2 | ✓ | ✓ | ✓ | – | – |
| m-ABC 2 | 5 | 124 | ✓ | ✓ | – | ✓ | 3–18.7 | ✓ | – | ✓ | – | – |
| FMA | 4 | 276 | - | ✓ | – | ✓ | 10.4–42.4 | ✓ | – | ✓ | – | – |
| MOON-test | 4 | 141 | ✓ | ✓ | ✓ | ✓ | 4–23 | ✓ | ✓ | ✓ | – | – |
| DMT 6–18 | 4 | 70 | ✓ | ✓ | ✓ | ✓ | 6–17 | – | ✓ | ✓ | – | – |
| GMFM | 4 | 62 | ✓ | – | – | – | 2–14.6 | ✓ | ✓ | ✓ | ✓ | ✓ |
| MOT 4–6 | 3 | 22 | ✓ | – | – | ✓ | 3.42–5.42 | – | ✓ | ✓ | – | – |
| Lincoln–Oseretzky Motor Development Scale | 1 | 45 | ✓ | – | – | ✓ | 5–14 | – | – | ✓ | – | – |
| FMS | 1 | 26 | ✓ | – | ✓ | ✓ | 5–8 | – | – | ✓ | – | – |
| GMFM – ALL | 1 | 20 | ✓ | – | – | – | 2.8–15.9 | ✓ | ✓ | - | ✓ | ✓ |
| UQAC-UQAM Test Battery | 1 | 20 | ✓ | – | – | – | 9–11 | – | – | ✓ | ✓ | – |
| Physical fitness battery test adapted by alpha-fitness-test-battery | 1 | 18 | ✓ | – | – | – | 7.55 ± 2.43 | – | – | ✓ | – | – |
| FITNESSGRAM | 1 | 10 | ✓ | – | ✓ | ✓ | 14.0–18.0 | ✓ | – | ✓ | – | - |
BOT Bruininks–Oseretsky Test, SF short form, m-ABC Movement Assessment Battery for Children, BOTMP Bruininks–Oseretsky Test of Motor Proficiency, FMA functional mobility assessment, MOON motor performance in pediatric oncology, DMT Deutscher Motorik Test, GMFM gross motor function measure, MOT Motoriktest für Kinder, FMS fundamental movement skills test battery, ALL acute lymphoblastic leukemia, UQAC-UQAM University of Québec in Chicoutimi-University of Québec in Montréal, maint. maintenance treatment, No. number.
aOnly study participants who performed the assessments were counted.
bIncluding other cancer diagnoses and diagnoses that were not clearly specified.
cIf evaluated in a childhood cancer population.
Summary of study methods assessing muscle strength in pediatric oncology.
| Assessment | No. of studies | Total sample sizea | Type of cancer | Age in years (range) | Phase of treatment | Validityc | Reliabilityc | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leukemia/ lymphoma | Bone tumor | CNS tumor | Otherb | During | Maint. | Off | ||||||
| Grip strength test | 27 | 4451 | ✓ | ✓ | ✓ | ✓ | 3.5–64 | ✓ | ✓ | ✓ | – | – |
| Hand held dynamometry | 17 | 830 | ✓ | ✓ | ✓ | ✓ | 4–58 | ✓ | ✓ | ✓ | – | ✓ |
| Isokinetic fynamometry | 10 | 3718 | ✓ | ✓ | ✓ | ✓ | 10.5–64 | – | ✓ | ✓ | – | ✓ |
| Sit-up test | 10 | 339 | ✓ | ✓ | ✓ | ✓ | 5–62.2 | ✓ | ✓ | ✓ | – | – |
| Push-up test | 6 | 239 | ✓ | ✓ | ✓ | ✓ | 4–62.2 | – | ✓ | ✓ | – | – |
| Manual muscle test | 6 | 165 | ✓ | ✓ | - | ✓ | 2–50+ | ✓ | ✓ | ✓ | – | – |
| Repetition maximum | 6 | 104 | ✓ | ✓ | ✓ | ✓ | 4–23 | ✓ | ✓ | ✓ | – | ✓ |
| Repeated squatting | 5 | 182 | ✓ | – | ✓ | ✓ | 6–30 | – | – | ✓ | – | – |
| Back extension test | 4 | 220 | ✓ | – | – | ✓ | 6–62.2 | – | – | ✓ | – | – |
| Isometric dynamometry | 3 | 143 | ✓ | – | – | ✓ | 5–30 | ✓ | – | ✓ | – | – |
| Chair-stand test | 3 | 100 | ✓ | – | ✓ | ✓ | 3.5–18 | ✓ | – | ✓ | – | – |
| Leg lift test | 2 | 128 | ✓ | – | – | – | 6–30 | – | – | ✓ | – | – |
| Vertical jump | 2 | 92 | ✓ | – | – | ✓ | 16–62.2 | – | – | ✓ | – | – |
| Shoulder lift test | 1 | 21 | ✓ | – | – | – | 16–30 | – | – | ✓ | – | – |
| Standing broad jump | 1 | 18 | ✓ | – | – | – | 7.55 ± 2.43d | – | – | ✓ | – | – |
| Lateral step test | 1 | 12 | ✓ | – | ✓ | – | 6–18 | – | – | ✓ | – | – |
maint. maintenance treatment, No. number.
aOnly study participants who performed the assessments were counted.
bIncluding other cancer diagnoses and diagnoses that were not clearly specified.
cIf evaluated in a childhood cancer population.
dNo information on minimum/maximum.
Summary of study methods assessing running speed in pediatric oncology.
| Assessment | No. of studies | Total sample sizea | Type of cancer | Age in years (range) | Phases of treatment | Validityc | Reliabilityc | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leukemia/lymphoma | Bone tumor | CNS tumor | Otherb | During | Maint. | Off | ||||||
| Shuttle run | 3 | 146 | ✓ | – | – | ✓ | 6–30 | – | – | ✓ | – | ✓ |
| 60 m run | 2 | 105 | ✓ | ✓ | ✓ | ✓ | 11 ± 3d | – | – | ✓ | – | – |
maint. maintenance treatment, No. number.
aOnly study participants who performed the assessments were counted.
bIncluding other cancer diagnoses and diagnoses that were not clearly specified.
cIf evaluated in a childhood cancer population.
dNo information on minimum/maximum.
Summary of study methods assessing balance in pediatric oncology.
| Assessment | No. of studies | Total sample sizea | Type of cancer | Age in years (range) | Phases of treatment | Validityc | Reliabilityc | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leukemia/lymphoma | Bone tumor | CNS tumor | Otherb | Active | Maint. | Off | ||||||
| SOT on dynamic posturography system (various): | 7 | 1805 | ✓ | – | ✓ | ✓ | 10–63.8 | – | – | ✓ | – | – |
| Balance tests (various) on force platforms | 4 | 292 | ✓ | ✓ | ✓ | ✓ | 4–25.2 | – | – | ✓d | – | – |
| Ultrasound-based motion analysis of postural sway | 1 | 22 | – | – | ✓ | – | 11–39 | – | – | ✓ | – | – |
| The Berg balance test | 1 | 156 | – | – | ✓ | – | 18–58 | – | – | ✓ | – | – |
| Flamingo balance test | 1 | 75 | ✓ | – | ✓ | ✓ | 11.3 ± 3.1e | ✓ | – | – | – | – |
| Single leg stance | 1 | 62 | ✓ | – | – | – | 1–22 | ✓ | – | – | – | – |
maint. maintenance treatment, No. number, SOT sensory organization test.
aOnly study participants who performed the assessments were counted.
bIncluding other cancer diagnoses and diagnoses that were not clearly specified.
cIf evaluated in a childhood cancer population.
dOne study was performed during inpatient rehabilitation potentially including patients still receiving maintenance treatment.
eNo information on minimum/maximum.
Summary of study methods assessing flexibility in pediatric oncology.
| Assessment | No. of studies | Total sample sizea | Type of cancer | Age in years (range) | Phases of treatment | Validityc | Reliabilityc | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leukemia/lymphoma | Bone tumor | CNS tumor | Otherb | During | Maint. | Off | ||||||
| Goniometry | 33 | 3764 | ✓ | ✓ | ✓ | ✓ | 1–64 | ✓ | ✓ | ✓ | – | ✓ |
| Sit and reach | 12 | 2830 | ✓ | ✓ | ✓ | ✓ | 4–64 | ✓ | ✓ | ✓ | – | – |
| Side-bending | 1 | 71 | ✓ | – | – | ✓ | 18.8–62.2 | – | – | ✓ | – | – |
maint. maintenance treatment, No. number.
aOnly study participants who performed the assessments were counted.
bIncluding other cancer diagnoses and diagnoses that were not clearly specified.
cIf evaluated in a childhood cancer population.
Summary of study methods assessing functional mobility in pediatric oncology.
| Assessment | No. of studies | Total sample sizea | Type of cancer | Age in years (range) | Phases of treatment | Validityc | Reliabilityc | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leukemia/lymphoma | Bone tumors | CNS tumors | Otherb | active | Maint. | Off | ||||||
| TUG 3 m | 25 | 4,283 | ✓ | ✓ | ✓ | ✓ | 3.5–64 | ✓ | ✓ | ✓ | ✓ | ✓ |
| TUDS | 13 | 314 | ✓ | ✓ | – | ✓ | 3.5–27 | ✓ | ✓ | ✓ | – | ✓ |
| TUG 10 m | 3 | 22 | ✓ | – | – | – | 4–16 | – | ✓ | ✓ | – | ✓ |
| Floor to stand performance | 1 | 62 | ✓ | – | – | – | 1–22 | ✓ | – | – | ||
| Stand up from bed rest exam | 1 | 11 | ✓ | – | – | ✓ | 3.5–15 | ✓ | – | – | ||
maint. maintenance treatment, No. number, TUDS timed up and down stairs test, TUG timed up and go test.
aOnly study participants who performed the assessments were counted.
bIncluding other cancer diagnoses and diagnoses that were not clearly specified.
cIf evaluated in a childhood cancer population.
Summary of study methods assessing gait in pediatric oncology.
| Assessment | No. of studies | Total sample sizea | Type of cancer | Age in years (range) | Phases of treatment | Validityc | Reliabilityc | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leukemia/lymphoma | Bone tumor | CNS tumor | Otherb | During | Maint. | Off | ||||||
| Video-recording and force platforms | 6 | 111 | – | ✓ | ✓ | ✓ | 3–35 | – | – | ✓d | – | – |
| Video-recording | 4 | 210 | – | ✓ | ✓ | ✓ | 4–24 | – | ✓ | ✓e | – | – |
| Video-recording, force plates and EMG | 3 | 67 | ✓ | ✓ | – | ✓ | 5–68.3 | – | ✓ | ✓ | – | – |
| GAITRite | 2 | 58 | ✓ | – | – | ✓ | 5–22 | ✓ | – | – | – | – |
| Visual observation | 1 | 62 | ✓ | – | – | – | 1–22 | ✓ | – | – | – | – |
| 10 m walk test | 1 | 16 | ✓ | – | ✓ | ✓ | 6–19 | – | ✓ | ✓ | – | – |
| Microgate optogait 2D Gait analysis system | 1 | 13 | ✓ | – | ✓ | ✓ | 6–15.8 | – | – | ✓ | – | – |
| EMG analysis (treadmill) | 1 | 8 | – | ✓ | – | – | N/Af | – | – | ✓ | – | – |
EMG electromyographic, maint. maintenance treatment, No. number.
aOnly study participants who performed the assessments were counted.
bIncluding other cancer diagnoses and diagnoses that were not clearly specified.
cIf evaluated in a childhood cancer population.
dOne study did not include this information, but inclusion criteria were at least one year post-surgery and completed adjuvant treatment program (without radiotherapy).
eOne study did not include this information, but stated 1–24 months after surgery.
f(age at surgery: 5–19 years and time since surgery 13–54 months).
Summary of the main findings.
| Main findings are… |
|---|
| 1. Physical function and performance were mostly evaluated after medical treatment. |
| 2. Leukemia patients formed the most examined group while solid tumors were less studied. |
| 3. Cardiorespiratory fitness and muscle strength were the physical outcomes of main interest. |
| 4. Assessments with the highest number of participants were |
| • 6 MWT ( |
| • Grip strength ( |
| • TUG 3 m ( |
| 5. Most assessments have not been evaluated for validity and reliability in pediatric cancer populations. |
6MWT 6-minute walk test, TUG timed up and go test.